U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545018) titled 'RAB001（LLP2A-Ale） in Healthy Subjects' on April 02.
Brief Summary: This trial is a single center, randomized, double-blind, placebo-controlled dose escalation study aimed at examining the safety, tolerability, and pharmacokinetics/pharmacodynamics of single and multiple injections of RAB001 in healthy subjects.
According to the results of Phase I clinical trials abroad, two dose groups (400 μ g/kg and 750 μ g/kg) were established, with 8 healthy subjects enrolled in each dose group (6 in the experimental group and 2 in the placebo group), for a total of 16 healthy subjects. Each dose group is divided into t...